AB1138 BONE SARCOIDOSIS: USEFULNESS OF 18F-FDG PET/CT
Authors: Lucie Demaria, Raphael Borie, Khadija Benali, Marine Forien, Philippe Dieudé, Bruno Crestani, Sebastien Ottaviani
Journal: Annals of the Rheumatic Diseases (2019)

<h3>Background</h3> Bone sarcoidosis: usefulness of <sup>18</sup>F-FDG PET/CT <h3>Objectives</h3> Bone sarcoidosis is usually rare but more sensitive imaging procedures such as <sup>18</sup>F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (<sup>18</sup>F-FDG PET/CT) allow a better characterization of such lesions. We aimed to describe bone sarcoidosis involvement using <sup>18</sup>F-FDG PET/CT. <h3>Methods</h3> We performed an observational retrospective study of patients with pulmonary sarcoidosis having a <sup>18</sup>F-FDG PET/CT. As stated by ATS/ERS/WASOG criteria, diagnosis of sarcoidosis was established on the presence of clinical symptoms and/or imaging features of sarcoidosis, and evidence of non-caseating epithelioid granuloma in a biopsy sample after exclusion of other known etiology of granuloma. We assessed clinical and <sup>18</sup>F-FDG PET/CT characteristics. <h3>Results</h3> A total of 85 patients (56.5% of female, median age 47 years) with sarcoidosis were analyzed. The median of disease follow-up was 4 years. Sarcoidosis occurred in more than three organs among 66% of cases. Using ATS/ERS/WASOG criteria, bone sarcoidosis was diagnosed in 12 (14%) patients. Spine was the most commonly affected bone (92%), followed by pelvis (67%), sternum (33%), humerus (25%) and fingers (17%). Only peripheral adenopathy was associated with bone lesions (<i>p</i>=0.04). Seven patients have benefited from a follow-up <sup>18</sup>F-FDG PET/CT, which in 100% of cases showed an improvement of lesions. <h3>Conclusion</h3> Bone sarcoidosis occurred in 14% of patients, affecting multiple bones and mostly the axial skeleton. <sup>18</sup>F-FDG PET/CT appears to be a sensitive imaging for diagnosis and follow-up of bone sarcoidosis. <h3>References</h3> [1] Aberg C, and al. AJR Am J Roentgenol. avr 2004 [2] Baldini S, and al. Br. J. Haematol. nov 2008 [3] Bechman K, and al. Rheumatology 1 mai 2018 [4] ClarenÇon F, and al. Spine. 15 sept 2007 [5] Conte G, and al. Ecancermedicalscience. 7 mai 2015 [6] Costabel U, and al. European Respiratory Society. World Association for Sarcoidosis and Other [7] Granulomatous Disorders. European Respiratory Journal. 1 oct 1999 [8] Glaudemans AWJM, and al. Journal of Immunology Research. 2013 [9] Grozdic Milojevic I, and al. Sarcoidosis Vasc Diffuse Lung Dis. 29 mars 2016 [10] James DG, and al. Ann. N. Y. Acad. Sci. 1976 [11] Judson MA, and al. Sarcoidosis Vasc Diffuse Lung Dis. 18 avr 2014 [12] Kaira K, and al. Chest. avr 2007 [13] Lefere M, and al. Clin Nucl Med. mars 2003 [14] Mostard RL, and al. Clin Nucl Med. janv 2012 [15] Prost N de, and al. RES. 2010 [16] Sparks JA, and al. Seminars in Arthritis and Rheumatism. 1 déc 2014 [17] Thelier N, and al.J. Rheumatol. août 2008 [18] Wilcox A, and al. Current Opinion in Rheumatology. juill 2000 [ [19] Zhou Y, and al. Seminars in Arthritis and Rheumatism. 1 févr 2017 [20] Zisman DA, and al. Semin Respir Crit Care Med. déc 2002 <h3>Disclosure of Interests</h3> None declared